Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases.
T M L TongM FioccoJ J van Duijn-de VreugdJ LutjeboerF M SpeetjensF G J TijlM E SitsenR W M ZoethoutC H MartiniA L VahrmeijerR W van der MeerC S P van RijswijkA R van ErkelE KapiteijnM C BurgmansPublished in: Cardiovascular and interventional radiology (2024)
M-PHP causes fatigue and a decline in physical and role functioning in the 1st weeks after treatment, but GHS returns to baseline levels within 21 days. LEVEL OF EVIDENCE 3: Cohort study.